Highlighted Paper selected by Editor-in-Chief : Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells
-
- Kaneko Naoki
- Drug Discovery Research, Astellas Pharma Inc.
-
- Yamanaka Kentaro
- Drug Discovery Research, Astellas Pharma Inc.
-
- Kita Aya
- Drug Discovery Research, Astellas Pharma Inc.
-
- Tabata Kenji
- Drug Discovery Research, Astellas Pharma Inc.
-
- Akabane Takafumi
- Drug Discovery Research, Astellas Pharma Inc.
-
- Mori Masamichi
- Drug Discovery Research, Astellas Pharma Inc.
書誌事項
- タイトル別名
-
- Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells
この論文をさがす
抄録
Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes, and effective treatment options are limited to cytotoxic agents, including microtubule-targeting agents, due to the lack of molecular targets. Here, we examined the combined effect of sepantronium bromide (YM155) and microtubule-targeting agents in TNBC models. The combination of YM155 with docetaxel showed synergistic antiproliferative and caspase 3/7-inducing effects in MRK-nu-1 and MDA-MB-453 human TNBC cell lines in vitro. YM155 also synergistically enhanced the efficacies of other microtubule-targeting agents, including paclitaxel and vinorelbine, which induced accumulation of survivin at the G2/M phase, whereas it did not affect the efficacy of doxorubicin. Combination treatment with YM155 and microtubule-targeting agents decreased the accumulation of survivin at the G2/M phase and induced greater apoptosis than either single agent alone. Further, combination treatment with YM155 and docetaxel also had a synergistic antitumor effect, achieving complete regression without exacerbation of body weight loss in all mice, in a MRK-nu-1 human TNBC xenograft model. These results suggest that survivin inhibition synergistically sensitize human TNBC cells to microtubule-targeting agents.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 36 (12), 1921-1927, 2013
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679610851072
-
- NII論文ID
- 130003361557
-
- NII書誌ID
- AA10885497
-
- COI
- 1:STN:280:DC%2BC2czmtVKktA%3D%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 025047412
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可